These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 8293759)

  • 1. New class III antiarrhythmic drugs.
    Katritsis D; Camm AJ
    Eur Heart J; 1993 Nov; 14 Suppl H():93-9. PubMed ID: 8293759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects].
    Steinbeck G
    Z Kardiol; 1992; 81 Suppl 4():139-43. PubMed ID: 1290290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential.
    Nair LA; Grant AO
    Cardiovasc Drugs Ther; 1997 Apr; 11(2):149-67. PubMed ID: 9140692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overview.
    Dorian P; Newman D
    Europace; 2000 Oct; 2(4):277-85. PubMed ID: 11194593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects.
    Kirchhof PF; Fabritz CL; Franz MR
    Circulation; 1998 Jun; 97(25):2567-74. PubMed ID: 9657478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias.
    Colatsky TJ; Follmer CH; Starmer CF
    Circulation; 1990 Dec; 82(6):2235-42. PubMed ID: 2242545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence.
    Hondeghem LM; Snyders DJ
    Circulation; 1990 Feb; 81(2):686-90. PubMed ID: 2153477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo Analysis of the Anti-atrial Fibrillatory, Proarrhythmic and Cardiodepressive Profiles of Dronedarone as a Guide for Safety Pharmacological Evaluation of Antiarrhythmic Drugs.
    Motokawa Y; Nakamura Y; Hagiwara-Nagasawa M; Goto A; Chiba K; Lubna NJ; Izumi-Nakaseko H; Ando K; Naito AT; Yamazaki H; Sugiyama A
    Cardiovasc Toxicol; 2018 Jun; 18(3):242-251. PubMed ID: 29139031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of Proarrhythmic Effects of Potassium Channel Blockers.
    Skibsbye L; Ravens U
    Card Electrophysiol Clin; 2016 Jun; 8(2):395-410. PubMed ID: 27261830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of action of class III anti-arrhythmia agents].
    Adamantidis MM
    Arch Mal Coeur Vaiss; 1995 Jan; 88 Spec No 1():33-40. PubMed ID: 7786143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of antiarrhythmic drugs.
    Lavenne F; de Jonghe D
    Acta Cardiol Suppl; 1980; (25):27-42. PubMed ID: 6155012
    [No Abstract]   [Full Text] [Related]  

  • 17. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates.
    Roden DM
    Am J Cardiol; 1996 Aug; 78(4A):12-6. PubMed ID: 8780324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent.
    Bargheer K; Bode F; Klein HU; Trappe HJ; Franz MR; Lichtlen PR
    Eur Heart J; 1994 Oct; 15(10):1409-14. PubMed ID: 7821321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proarrhythmic actions of antiarrhythmic drugs: a review.
    Campbell TJ
    Aust N Z J Med; 1990 Jun; 20(3):275-82. PubMed ID: 2196873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postrepolarization refractoriness in acute ischemia and after antiarrhythmic drug administration: action potential duration is not always an index of the refractory period.
    Coronel R; Janse MJ; Opthof T; Wilde AA; Taggart P
    Heart Rhythm; 2012 Jun; 9(6):977-82. PubMed ID: 22293142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.